ES2045404T3 - Composiciones para tratar tumores intracraneales. - Google Patents

Composiciones para tratar tumores intracraneales.

Info

Publication number
ES2045404T3
ES2045404T3 ES89301258T ES89301258T ES2045404T3 ES 2045404 T3 ES2045404 T3 ES 2045404T3 ES 89301258 T ES89301258 T ES 89301258T ES 89301258 T ES89301258 T ES 89301258T ES 2045404 T3 ES2045404 T3 ES 2045404T3
Authority
ES
Spain
Prior art keywords
drug
migration
administration
tumors
intracraneal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89301258T
Other languages
English (en)
Inventor
Edward E Luck
Dennis M Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matrix Pharmaceutical Inc
Original Assignee
Matrix Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Pharmaceutical Inc filed Critical Matrix Pharmaceutical Inc
Application granted granted Critical
Publication of ES2045404T3 publication Critical patent/ES2045404T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fertilizers (AREA)

Abstract

MASAS CELULARES SOLIDAS ANORMALES INTRACELULARES, PARTICULARES TUMORES O TEJIDOS ADYACENTES QUE PUEDEN CONTENER CELULAS TUMORAL, SE TRATAN POR ADMINISTRACION A LA ZONA ANORMAL UNA CANTIDAD SUFUCIENTE DE DROGA CITOTOXICA QUE COMPRENDE UN ALCALOIDE DE LA VINCA DISPERSO EN UNA MATRIZ PROTEINACEA FLUIDA ESTABLE. LA MATRIZ INHIBE SUSTANCIALMENTE LA MIGRACION DE LA DROGA DEL LUGAR DE ADMINISTRACION, DE MODO QUE MANTIENE EL EFECTO PRIMARIO DE LA DROGA EN LA REGION DE ADMINISTRACION. LA MIGRACION SE PUEDE INHIBIR CON EL USO DE MATERIALES ACEPTABLES FISIOLOGICAMENTE QUE MODIFIQUEN LAS PROPIEDADES CELULARES O RESPUESTAS FISIOLOGICAS PARA REGIONALIZAR DESPUES LA COLOCACION DEL FARMACO EN EL PUNTO DE INYECCION.
ES89301258T 1988-02-11 1989-02-09 Composiciones para tratar tumores intracraneales. Expired - Lifetime ES2045404T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15498488A 1988-02-11 1988-02-11

Publications (1)

Publication Number Publication Date
ES2045404T3 true ES2045404T3 (es) 1994-01-16

Family

ID=22553654

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89301258T Expired - Lifetime ES2045404T3 (es) 1988-02-11 1989-02-09 Composiciones para tratar tumores intracraneales.

Country Status (7)

Country Link
EP (1) EP0328389B1 (es)
JP (1) JP2862175B2 (es)
AT (1) ATE77754T1 (es)
CA (1) CA1330422C (es)
DE (1) DE68901931T2 (es)
ES (1) ES2045404T3 (es)
GR (1) GR3005841T3 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5750146A (en) * 1995-04-28 1998-05-12 Matrix Pharmaceutical, Inc. Translucent collagen formulations with a cytotoxic drug
DE10037983B4 (de) * 2000-08-03 2006-04-13 Stefan Zikeli Polymerzusammensetzung und daraus hergestellter Formkörper mit einem Gehalt an Alkaloid
JP2003119156A (ja) * 2001-08-06 2003-04-23 Kikuji Yamashita コラーゲンを含有する口腔用剤、医薬品および医薬部外品
CN1923281B (zh) * 2005-08-30 2010-05-05 孔庆忠 一种含植物生物碱的抗癌缓释注射剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU179753B (en) * 1977-10-13 1982-12-28 Richter Gedeon Vegyeszet Process for producting synergetic pharmaceutical compositions of citostatic activity
US4619913A (en) * 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas

Also Published As

Publication number Publication date
DE68901931D1 (de) 1992-08-06
JPH021406A (ja) 1990-01-05
EP0328389B1 (en) 1992-07-01
CA1330422C (en) 1994-06-28
ATE77754T1 (de) 1992-07-15
EP0328389A3 (en) 1989-10-11
GR3005841T3 (es) 1993-06-07
EP0328389A2 (en) 1989-08-16
JP2862175B2 (ja) 1999-02-24
DE68901931T2 (de) 1992-12-10

Similar Documents

Publication Publication Date Title
ES2272827T3 (es) Parche terapeutico transdermico con capsaicina y analogos de capsaicina.
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
DE3579068D1 (de) Arzneimittelenthaltende matrizen fuer einfuehrungen in zonen mit cellularen lesionen.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
DK0503440T3 (da) Sumatriptanholdige lægemidler
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
LU92154I2 (fr) Axitinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
NZ541593A (en) Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
KR970702060A (ko) DNA 손상제 및 p53을 포함하는 조성물(Compositions comprising DNA damaging agents and p53)
WO2001039762A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
HUT43948A (en) Emulsion compositions for dosing ionizable hydrophobic medical substances which are little soluble in water and process for preparing the same
SK137996A3 (en) Cancer treatment and metastasis prevention
ES2045404T3 (es) Composiciones para tratar tumores intracraneales.
BR0315316A (pt) Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
RU2005126819A (ru) Усовершенствованное лечение опухолей
AU2003276041A8 (en) Mucuna pruriens and extracts thereof for the treatment of neurological diseases
ATE334590T1 (de) Anti-arrhythmische zusammensetzungen und behandlungsverfahren
DE3786456T2 (de) Kombinationen von nekrose-tumor-faktoren und entzündungshemmenden mitteln für die behandlung von bösartigen und nicht bösartigen erkrankungen.
MXPA03007743A (es) Combinacion de un taxano y una cinasa dependiente de ciclina.
EA200400348A1 (ru) Цисплатиновые составы пониженной токсичности и способы их применения
White et al. Evaluation of response to chemotherapy in retinoblastoma heterotransplanted to the eyes of nude mice
ZA200605900B (en) Glycosylated steroid derivatives with anti-migratory activity
EP0272393A3 (en) Pharmaceutical combination
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 328389

Country of ref document: ES